Cytokines in mice treated with amphotericin B-intralipid

Medical Mycology

Volumn 42, Issue 2, 2004, Pages 123-128

  Shadkchan, Y ^a   Keisari, Y ^a   Segal, Esther ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Amphotericin B; Cytokines; Intralipid; Mice

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BETA ACTIN; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG USE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STUDENT T TEST;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CYTOKINES; FAT EMULSIONS, INTRAVENOUS; FEMALE; MICE; MICE, INBRED ICR; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; CANDIDA;

EID: 1842863524     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780310001624583     Document Type: Article

References (24)

1. Shadkchan Y, Segal E, Bor A, Gov Y, Rubin M, Lichtenberg D. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J Antimicrob Chemother 1997; 39: 655-658.
2. Shadkchan Y, Segal E. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naïve mice. J Antimicrob Chemother 1999; 44: 787-790.
3. Shadkchan Y, Segal E. Treatment of experimental candidosis with amphotericin B-Intralipid admixtures in immunocompromised mice. J Antimicrob Chemother 2001; 48: 245-251.
4. Shadkchan Y, Zaslavsky Z, Segal E. Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-Intralipid. Med Mycol 2002; 41: 15-19.
5. Benson JM, Nahata MC. Clinical use of systemic antifungal agents. Clin Pharmacol 1988; 7: 424-38.
6. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B. Current understanding of mechanism of action. Antimicrob Agents Chemother 1990; 34: 183-188.
7. Gallis HA. Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clin Infect Dis 1996; 22: s145-147.
8. Barton CH, Pahl M, Vaziri ND, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am J Med 1984; 77: 471-74.
9. Vonk AG, Netea MG, Denecker N, Verschuueren I, van der Meer J, Kullberg BJ. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. J Antimicrob Chemother 1998; 42: 469-474.
10. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995; 38: 459-465.
11. Benedict S, Colagreco J. Fungal infections associated with malignancies, treatments and AIDS. Canc Nurs 1994; 17: 411-7.
12. Bodey GP, MA Luna. Disseminated candidiasis in patients with acute leukemia. Clin Infect Dis 1998; 27: 238.
13. Borzotta AP, K Beardsley. Candida infections in critically ill trauma patients. A retrospective case-control study. Arch Surg 1999; 134: 657-664.
14. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multi-center surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000; 30: 14-18.
15. De Pauw BE, Meunier F. The challenge of invasive fungal infection. Chemotherapy 1999; 45: 1-14.
16. De Marie S. New development in the diagnosis and management of invasive fungal infections. Haematologica 2000; 85: 88-93.
17. Aoun M. Standard antifungal therapy in neutropenic patients. Int J Antimicrob Agents 2000; 16: 143-145.
18. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Safety 1990; 5: 94-108.
19. Bolard J, Seignemet M, Boudet G. Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B. Biochim Biophys Acta 1980; 599: 280-293.
20. Elewski BE. Mechanism of systemic antifungal agents. J Am Acad Derm 1993; 28: 928-934.
21. Rogers PD, Kramer RE, Chapman SW, Cleary JD. Amphotericin B-induced interleukin-1b expression in human monocytic cells is calcium and calmodulin dependent. J Infect Dis 1999; 180: 159-166.
22. Mencacci A, Cenci E, Bacci A, Bistoni F, Romani L. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis. J Infect Dis 2000; 181: 686-694.
23. Romani L. Cytokine modulation of specific and nonspecific immunity to Candida albicans. Mycoses 1999; 42: 45-48.
24. Chia JK, Mcmanus EJ. In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob Agents Chemother 1990; 34: 906-908.